8-K: INVO Fertility Completes Family Beginnings Acquisition

INVO Fertility, Inc. has successfully closed the acquisition of Family Beginnings, P.C., expanding its network of fertility care centers and broadening patient access to advanced reproductive care.

Summary

• INVO Fertility, Inc. (Nasdaq: IVF) completed the acquisition of Family Beginnings, P.C., an Indiana-based fertility clinic, on February 18, 2026.
• The total purchase price for the acquisition was $760,000, comprising $360,000 in cash (net $210,000 after a $150,000 holdback) and $400,000 paid in 400 shares of INVO's Series D Preferred Stock.
• The acquisition involved Wood Violet Fertility LLC (an INVO subsidiary) purchasing non-medical assets and entering into a Management Services Agreement (MSA) with Fertility, P.A. (a new entity that acquired the clinic's medical assets for $100).
• The MSA has an initial term of ten years, automatically renewing for five-year terms, with a management fee equal to 20% of the Manager's Costs.
• Family Beginnings generated approximately $1 million in revenue and $0.2 million in net income for the nine months ended September 30, 2025, representing approximately 18% of INVO's clinic revenue for the same period.
• A lease agreement was executed for 4,387 square feet at 8435 Clearvista Plaza, Indianapolis, Indiana, with an initial term ending July 31, 2033, and annual base rent starting at $132,398.61 (after 3 months of abated rent), increasing 2% annually.
• The Series D Preferred Stock issued has a stated value of $1,000 per share, an initial conversion price of $1.20 per share (subject to adjustments but not below a Floor Price), and carries no voting rights.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it represents the successful execution of a stated growth strategy through acquisition and expands the company's market presence in a key region. The retention of key personnel and the strategic alignment are favorable, though the financial impact of this specific acquisition is relatively small compared to the overall company.

Positives

• Expands INVO Fertility's geographic footprint and enhances its portfolio of clinics, aligning with its strategic growth outlook.
• Advances the company's mission of increasing access to high-quality, patient-centered fertility care.
• Family Beginnings has a strong reputation for excellence and compassionate care, which aligns closely with INVO's mission and values.
• Existing medical leadership and care teams, including Dr. James Donahue (a recognized '2026 Castle Connolly Top Doctor'), will remain in place, ensuring continuity of care for patients.
• The acquired clinic is expected to benefit from INVO's broader clinical resources, operational support, and ongoing investment in advanced technologies and best practices.
• The company highlights that it is enjoying its 'strongest fundamental position in several years,' suggesting a positive internal assessment of its overall health.
• The lease agreement includes three months of abated base rent and a tenant allowance of $109,675.00 for leasehold improvements, reducing initial occupancy costs.

Negatives

• The acquisition involves a complex legal structure with multiple agreements (MSA, PC APA, Lease, Series D Preferred terms), which could increase administrative complexity and potential for disputes.
• The Management Fee structure, set at 20% of 'Manager's Costs,' could be opaque and potentially lead to conflicts of interest if not managed with full transparency.
• The Series D Preferred Stock includes weighted average price-based adjustments, which could be dilutive to common shareholders if future equity is issued at a lower price.
• The beneficial ownership limitation (4.99%, adjustable to 9.99%) on Series D Preferred conversion may restrict a holder's ability to convert a large block of shares quickly, potentially affecting liquidity for the preferred shareholder.
• The Exchange Cap under NASDAQ Listing Rule 5635(d) may require shareholder approval for the full conversion of the Series D Preferred Stock, introducing an element of uncertainty and potential delays.

Risks

• Integration Risk: Challenges in successfully integrating Family Beginnings' operations, culture, and patient base into INVO's existing network, despite the retention of key personnel.
• Regulatory Compliance Risk: Ongoing need to navigate and comply with complex federal and state healthcare laws and regulations (e.g., Anti-Kickback Law, Stark Law, HIPAA) across all new contractual arrangements.
• Financial Performance Risk: While positive, the acquired clinic's historical revenue ($1 million) and net income ($0.2 million) for a nine-month period are relatively small, representing only 18% of INVO's clinic revenue, which may limit the immediate material financial impact on the overall company.
• Dilution Risk: The conversion features of the Series D Preferred Stock, particularly the weighted average price-based adjustments, could lead to future dilution for existing common shareholders.
• Lease Obligation Risk: Long-term lease commitment for the Indianapolis premises, with annual rent increases and potential for additional costs from Excess Operating Expenses, exposes the company to real estate market fluctuations and operational cost increases.
• Dispute Resolution Risk: The various agreements contain detailed dispute resolution procedures, indicating the potential for disagreements in complex contractual relationships, which could incur legal costs and management distraction.

Future Outlook

INVO Fertility aims to expand its network of fertility care centers and broaden patient access to advanced reproductive care through both organic initiatives and targeted clinic acquisitions. The company expects to build on Family Beginnings' legacy and grow the clinic from its current operating levels, leveraging INVO's broader clinical resources, operational support, and investment in advanced technologies and best practices. The company also states it is in its strongest fundamental position in several years.

Management Comments

• "We are thrilled to complete the acquisition of Family Beginnings. This transaction not only expands our geographic footprint and enhances our portfolio of clinics, but it also advances our mission of increasing access to high-quality, patient-centered fertility care."
• "Family Beginnings has a long-standing reputation for excellence and compassionate care, and we look forward to building on that legacy with Dr. Donahue and growing the clinic from its current operating levels."

Industry Context

StockSavvy.ai notes that the acquisition of Family Beginnings P.C. by INVO Fertility aligns with a broader trend in the healthcare industry towards consolidation and specialization, particularly in high-growth sectors like fertility services. The emphasis on expanding access to advanced reproductive technology (ART) and leveraging INVOcell technology positions the company to capitalize on increasing demand for fertility treatments. The retention of key medical personnel like Dr. James Donahue is crucial for maintaining patient trust and operational continuity in a service-oriented medical field.

Comparison to Industry Standards

• The acquisition of a clinic generating $1 million in revenue and $0.2 million in net income for a 9-month period, for a total consideration of $760,000, suggests a valuation multiple that StockSavvy.ai would compare against recent transactions in the fertility clinic sector. For example, larger fertility clinic networks like IVI-RMA Global or Prelude Fertility often acquire smaller practices at multiples ranging from 5x to 10x EBITDA, depending on growth prospects and strategic fit.
• The 20% management fee based on 'Manager's Costs' in the MSA is a common structure in physician practice management, but its competitiveness depends on the scope of services and the transparency of 'Manager's Costs' compared to benchmarks from companies like OptumCare or Envision Healthcare's physician services divisions.
• The initial conversion price of $1.20 for Series D Preferred Stock, subject to weighted average price-based adjustments, is a common anti-dilution protection seen in venture-backed or growth-stage companies, similar to terms found in preferred stock issuances by biotech or emerging healthcare firms.

Management Changes

Corporate Governance

Related Party Transactions

• Wood Violet Fertility LLC, a wholly-owned subsidiary of INVO Centers LLC (which is wholly-owned by INVO Fertility, Inc.), entered into a Management Services Agreement with Fertility, P.A. (the acquired entity).
• Fertility, P.A. (New PC) acquired clinical assets from Family Beginnings, P.C. (Company), which was acquired by INVO.
• James Donahue, MD, the seller, received Series D Preferred Stock from INVO Fertility, Inc. as part of the acquisition consideration and will continue to lead the clinic under a multi-year agreement.

Stakeholder Impact

• Shareholders (INVO Fertility): Potential for long-term growth and market expansion, but also potential for dilution from Series D Preferred Stock conversion. The acquisition is relatively small in financial terms compared to INVO's existing clinic revenue.
• Employees (Family Beginnings): Continuity of care teams and medical leadership, with New PC offering employment to clinical employees, including Dr. James Donahue.
• Customers (Patients of Family Beginnings): Expected continuity of high-quality, personalized fertility care, potentially enhanced by INVO's broader resources and advanced technologies like INVOcell.
• Management (INVO Fertility): Successful execution of a strategic growth initiative, expanding the company's operational footprint.

Next Steps

• Integration of Family Beginnings P.C. into INVO Fertility's operational network.
• Dr. James Donahue will continue to lead the clinic's operations under a multi-year agreement.
• Leveraging INVO's clinical resources, operational support, and investment in advanced technologies to grow the acquired clinic.
• Ongoing compliance with the terms of the Management Services Agreement, PC Asset Purchase Agreement, and Lease Agreement.
• Potential future conversions of Series D Preferred Stock into common stock by the holder.

Key Dates

Recommendation

The acquisition of Family Beginnings P.C. is a positive step in INVO Fertility's stated growth strategy, expanding its geographic reach and integrating a reputable clinic. The retention of key medical personnel and the strategic alignment with INVO's mission are favorable. However, the financial impact of this specific acquisition is relatively modest, and the issuance of convertible preferred stock introduces potential future dilution. While the company reports being in its 'strongest fundamental position in several years,' a 'hold' recommendation is appropriate as investors should monitor the successful integration, the realization of synergies, and the broader financial performance of INVO Fertility to assess the long-term value creation from this and future acquisitions.

Keywords

Fertility Clinic Acquisition, INVO Fertility, Family Beginnings, Healthcare Services, Reproductive Technology, IVF, INVOcell, Management Services Agreement, Preferred Stock, Corporate Growth, Indiana, Medical Practice Management